Eleven Therapeutics Overview
Eleven Therapeutics is a startup at the forefront of mRNA therapeutics innovation. The company’s xRNA modality-based pipeline is aimed to create extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. TERÅ is a proprietary high-throughput platform designed to screen thousands of xRNA molecules in order to identify non-canonical elements that possess superior stability and safety characteristics, amenable for a multitude of chronic therapeutic applications, including the newly announced fibrotic disorders.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Eleven Therapeutics Welcomes Dr. Paloma H Giangrande as Chief Technology Officer
Eleven Therapeutics, a biotechnology company specializing in mRNA therapeutics, has appointed Dr. Paloma H Giangrande as its Chief Technology Officer (CTO). Dr. Giangrande is a leader in the field of nucleic acid therapeutics and has held key leadership roles at renowned biotechnology companies, including Moderna and Wave Life Sciences. In her new role, she will drive the strategic direction for Eleven Therapeutics core xRNA technologies and platforms. The companys CEO, Prof. Yaniv Erlich, expressed his enthusiasm about Dr. Giangrande joining the team, stating that her appointment represents a strategic milestone for the company.
Management Changes
growth-positive
Dong-A ST Signs R&D Agreement with Eleven Therapeutics for RNA-based Gene Therapy
South Korean pharmaceutical company Dong-A ST has signed a business agreement with Eleven Therapeutics to develop RNA-based gene therapies. The partnership will focus on discovering RNA therapies for fibrotic diseases using Eleven Therapeutics TERA platform technology, which uses AI and machine learning to decode high-throughput RNA chemical modifications. This collaboration aligns with Dong-A STs strategy of expanding its R&D capabilities in the field of gene therapy.
PartnersExpand
growth-positive
Eleven and Novo Nordisk partner to develop nucleic acid therapeutics - Pharmaceutical Technology
Eleven Therapeutics and Novo Nordisk have announced a research partnership to identify novel nucleic acid molecules to treat cardiometabolic diseases using Eleven’s DELiveri platform. The DELiveri platform uses AI and machine learning in combination with DNA-encoded libraries to find conjugates that can transport therapeutic molecules. Novo Nordisk will have exclusive rights to specific cell types and applications developed using the DELiveri platform. This partnership is part of a series of investments made by Novo Nordisk, including an expansion of its manufacturing facilities in Denmark and a partnership with Aspect Biosystems.
PartnersInvestment
Growth-Positive
"We are revolutionizing the world of RNA" | CTech
Yaniv Erlich, CEO of Eleven Therapeutics, spoke at the Mind the Tech conference in London, stating that his company is revolutionizing the world of RNA. The conference, which is an annual event by Calcalist, focused on the changes experienced by the high-tech sector over the past year. It assessed the impact of market shakeups on the high-tech economy and reviewed upcoming trends in the technology world.
growth-positive
Eleven Therapeutics Raises $22M in Seed Funding - FinSMEs
Eleven Therapeutics, a biotechnology company focused on advancing nucleic acid therapeutics, has raised $22 million in seed funding. The funding includes a $9 million commitment from the Bill and Melinda Gates Foundation, with $5 million towards future equity investment and $4 million as a non-dilutive grant. The funding will support the development of a platform that designs small interfering RNAs (siRNAs) with ultra-long durability. Eleven Therapeutics aims to develop siRNA treatments for respiratory diseases using its flagship invention, SCSI-RNA™. The company has collaborative hubs in Cambridge, UK; Boston, US; and Tel Aviv, Israel. The funding will also promote wide accessibility of Elevens treatments to people in need in developing countries.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $25.9M |
| Last funding | $22M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 3 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | eleventx.com/ |
| Careers | Careers page |
Locations
Ben Yehuda Street 99, Tel Aviv-Yafo, Israel
Boston, MA, USA
Robinson Way, Cambridge, UK
Photos & Videos
No files yet
